Pfizer (PFE) Expands LITFULO's Potential with Positive Phase 3 Vitiligo Results
Pfizer's LITFULO shows promise in treating vitiligo, presenting a strategic growth opportunity for investors.
Outlook Therapeutics (OTLK) Faces Market Skepticism Post-FDA Approval of LYTENAVA
Outlook Therapeutics faces skepticism despite FDA approval for LYTENAVA, with shares plummeting 36.3%.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
MiMedx Expands Portfolio with Sanara MedTech Acquisition: What Investors Need to Know
MiMedx's $35 per share acquisition of Sanara MedTech marks a significant move in the regenerative medicine sector.
IonQ's Path to Quantum Computing: SkyWater Acquisition Approved
IonQ's acquisition of SkyWater is a strategic move towards enhancing its quantum computing capabilities.
ICE-MarketAxess Deal: A $6 Billion Shift in US Fixed-Income Trading
The $6 billion acquisition of MarketAxess by ICE signals a transformative shift in the US fixed-income trading landscape…
Victory Square Technologies: FDA Approval Signals Growth Potential in Peptide Therapeutics
Victory Square Technologies eyes growth in peptide therapeutics following favorable FDA advisory committee recommendatio…
Moderna and Regeneron: Diverging Paths Ahead of Key Biotech Catalysts
Moderna's price surges ahead of an FDA ruling, while Regeneron faces market challenges despite strong earnings.
Humana's Q2 Performance: A Mixed Bag for Investors in the Pharmaceutical Sector
Humana's Q2 earnings exceeded estimates but left some analysts wanting more, raising questions about the managed care se…
Regulatory Changes Impacting Victory Square's Healthcare Ventures
Victory Square Technologies faces new challenges as FDA recommendations could reshape its healthcare portfolio.
United Therapeutics' Ralinepag: A Potential Breakthrough for PAH Treatment
United Therapeutics' ralinepag shows promise in treating pulmonary arterial hypertension, potentially boosting revenue a…
Amgen's MariTide Trials: A Game Changer in the GLP-1 Market?
Amgen's Phase 3 trials for MariTide could disrupt the GLP-1 landscape, intensifying competition with Eli Lilly and Novo …